FDA Approves Palladia Drugs for Dogs Cancer Treatment


To treat cancer in dogs the Food and Drug Administration has agreed the first specifically made drug. Till now, all the drugs developed for human and the drug weren’t especially approved for animals like dogs. Under the Federal law, expertise allows administering cancer medicines as well as other human treatments under controlled situations. Pfizer Animal Health Inc. manufactured a new drug called ‘Palladia’. The Palladia drug has been permitted to treat cases of canine skin tumors. According to the FDA, Canine cutaneous mast cell tumors can appear minor as well as insignificant, but some of the are effortlessly removed and others can lead to life-threatening disease.

Mast cell tumor (MCT) is common skin tumor in dogs, MCT represents cancer of blood cell normally involved in the body’s response to tenderness. Mast cell tumor can affect another area of the body such as the spleen, liver as well as bone marrow. Director of FDA’s Center for Veterinary Medicine, Mr. Bernadette Dunham said, “This cancer drug approval for dogs is an important step forward for veterinary medicine”. Mr. Bernadette Dunham stated, “Prior to this approval, veterinarians had to rely on human oncology drugs, without knowledge of how safe or effective they would be for dogs”. Further, Mr. Dunham said, “Today’s approval offers dog owners, in consultation with their veterinarian, an option for treatment of their dog’s cancer”. The new drug ‘Palladia’ is a tyrosine kinase inhibitor that operated to kill tumor cells as well as cutting off blood supply to the tumor. There are some common side effects of the drug such as loss of hunger, weight loss, loose motion, lameness.